Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis
Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S. Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J. Goebell · 2024
Read Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis by Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S. Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J. Goebell (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646210.txt.
Description
Frazer and a large team reviewed in twenty twenty-four when a single drug is the best first care for spread kidney cancer. Mix care with two drug kinds is now common, but it is not right for all. They focus on one drug, tivozanib, that blocks a growth switch for blood vessels.
For folks with a good outlook, long-term data back single-drug care with fair life and life quality. This drug matches peers on strength but has fewer off-target side harms. The choice turns on risk class, age, other ills, and what the patient values most. Guides still list single-drug care as a norm for the good-outlook group.
Catalog record
| CREATOR | Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S. Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J. Goebell |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |